# Seattle Sperm Bank – FDA 483, Jun 19, 2026

Source: https://www.keypedia.com/records/483/seattle-sperm-bank/10e3f0d7-5519-4e3b-9dad-1db97f360cfe

> FDA 483 for Seattle Sperm Bank on June 19, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Seattle Sperm Bank
- Inspection Date: 2026-06-19
- Product Type: biologics
- Office Name: San Francisco District Office
- Summary: Seattle Sperm Bank in Las Vegas, NV, was cited for deficiencies in its donor screening and eligibility procedures during an FDA inspection. The firm failed to adequately screen HCT/P donors for communicable disease risks and lacked proper instructions in its standard operating procedures for determining donor eligibility. These issues indicate a moderate level of concern regarding donor safety and compliance with regulatory requirements.

## Related Officers

- [Emily S. McGann](https://www.keypedia.com/people/emily-s-mcgann/43891ff3-bd70-4337-b61c-e16cc7ad0468)
- [James A. Banks](https://www.keypedia.com/people/james-a-banks/6838e911-c630-4a7c-8198-f3936ef6c5f8)
- [Fabian N. Chaparro-rodriguez](https://www.keypedia.com/people/fabian-n-chaparro-rodriguez/f14fd931-0830-4a84-a287-2dd85e40195d)

Company: https://www.keypedia.com/companies/seattle-sperm-bank/9c8e5d96-4632-44a1-a500-52ad4bb61aa9

Office: https://www.keypedia.com/offices/san-francisco-district-office/6f838e9c-aae1-4665-9c46-a51d43be02df